GSK plc vs Target Corporation — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Target Corporation trades at $153.77 (market cap $70.31B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Target Corporation for 137 Days on average.
| GSK | TGT | |
|---|---|---|
Market Cap | $91.88B | $70.31B |
Volume | 7,730,529 | 4,164,999 |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $169.90 |
52-Week Low | $43.24 | $83.68 |
Typical Hold Time | 93 Days | 137 Days |
Enterprise Value | $111.88B | $83.58B |
Dividend Yield | 3.9% | 3% |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Target Corporation (TGT) trades at $154.76, up 2.52% with strong recent earnings beats. The stock shows bearish technical signals but maintains solid fundamentals with a 26.41% ROE and 4.08% net margin. Recent price cuts on 2,000 items aim to capture holiday market share, while analyst consensus targets $167.18 with 47% buy ratings. Cash flow remains positive at $957M despite competitive retail pressures.
Target presents a mixed outlook with valuation appeal (P/E 16.05) against bearish technicals. Upside potential exists from continued earnings outperformance and dividend stability, but risks include margin pressure from price investments and weak consumer spending. The stock offers value for patient investors despite near-term volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →